Aptcash Enterprises
Parel, Mumbai, Maharashtra
GST No. 27BDTPM3418D1ZF
TrustSEAL Verified
View Mobile No.
SEND EMAIL

Anticancer Medicine

Prominent & Leading Wholesale Trader from Mumbai, we offer ibritinib lymphocytic leukemia ib tib 140mg cap, anti-cancer, cadila pharma, bosutinib 400 mg 30 tab , 500mg 30 tab , 100mg 60 tab bosuvi glenmark, zelgor tablets, lenangio capsules, soranib sorafenib tablets and advacan tablets.

Ibritinib Lymphocytic Leukemia Ib Tib 140mg Cap, Anti-Cancer, Cadila Pharma

Ibritinib Lymphocytic Leukemia Ib Tib 140mg Cap, Anti-Cancer, Cadila Pharma
  • Ibritinib Lymphocytic Leukemia Ib Tib 140mg Cap, Anti-Cancer, Cadila Pharma
  • Ibritinib Lymphocytic Leukemia Ib Tib 140mg Cap, Anti-Cancer, Cadila Pharma
  • Ibritinib Lymphocytic Leukemia Ib Tib 140mg Cap, Anti-Cancer, Cadila Pharma
  • Ibritinib Lymphocytic Leukemia Ib Tib 140mg Cap, Anti-Cancer, Cadila Pharma
  • Ibritinib Lymphocytic Leukemia Ib Tib 140mg Cap, Anti-Cancer, Cadila Pharma
  • Ibritinib Lymphocytic Leukemia Ib Tib 140mg Cap, Anti-Cancer, Cadila Pharma
Ask For Price
Product Price :Get Latest Price
Product Brochure

Product Details:

Packaging Size140mg 90 capsule bottle
BrandIb Tib
CompositionIbrutinib
ManufacturerCadila Pharma
TreatmentB cell cancers like mantle cell lymphoma,chronic lymphocytic leukemia,and Waldenstrom's macroglob
Packaging140mg,90capsule bottle
Dose Strength140mg
CategoryBlood Cancer
DrugIbrutinib
Generic NameIbrutinib
Dosage FormOral
Packaging Type140mg,90capsule bottle
FormCapsule
Therapeutic Useschronic lymphocytic leukemia (CLL),Waldenstrom's macroglobulinemia,and as a second-line treatment
Side Effectpneumonia,upper respiratory tract infection,sinusitis,skin infection,low neutrophil count,low
Strength140mg,90 capsule bottle

Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK), that is important in B cells. It is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.

Medical uses
Ibrutinib is used to treat chronic lymphocytic leukemia (CLL), Waldenström's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, marginal zone lymphoma, and chronic graft vs host disease.

In the United States ibrutinib is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with or without 17p deletion, adults with Waldenström's macroglobulinemia (WM), adults with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy, adults with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

It is a first line treatment in those with CLL who require treatment and are newly diagnosed. CLL relapase.

ResistanceBoth primary (inherent) and secondary (acquired) resistance has been reported in various lymphomas, including CLL and MCL.Resistance may arise due to mutations that impair the affinity of ibrutinib for BTK, or due to alterations in pathways downstream of BTK and may confer BCR signaling independence in resistant clones.
Adverse effects
Very common (>10% frequency) adverse effects include pneumonia, upper respiratory tract infection, sinusitis, skin infection, low neutrophil count, low platelet counts, headache, bleeding, bruising, diarrhea, vomiting, inflammation of mouth and lips, nausea, constipation, rash, joint pain, muscle spasms, musculoskeletal pain, fever, and edema.

Common (1–10% frequency) adverse effects include sepsis, urinary tract infection, non-melanoma skin cancer (basal-cell carcinoma, squamous cell carcinoma), low leukocyte count, low lymphocyte count, interstitial lung disease, tumor lysis syndrome, high uric acid levels, dizziness, blurred vision, atrial fibrillation, subdural hematoma, nosebleeds, small bruises from broken blood vessels, high blood pressure, hives, and skin redness or blushing.
Pharmacology
Ibrutinib oral bioavailability is 3.9% in a fasting state, 8.4% in a fed state, and 15.9% after consumption of grapefruit juice.
Mechanism
Ibrutinib to reduce chronic lymphocytic leukemia cell chemotaxis towards the chemokines CXCL12 and CXCL13, and inhibit cellular adhesion following stimulation at the B-cell receptor (BCR).Additionally, ibrutinib down-modulates the expression of CD20 (target of rituximab/ofatumumab) by targeting the CXCR4/SDF1 axis.Together, these data are consistent with a mechanistic model whereby ibrutinib blocks BCR signaling, which drives cells into apoptosis and/or disrupts cell migration and adherence to protective tumour microenvironments.
Request
Callback


Additional Information:

  • Packaging Details: 140mg , 90cap bottle
Yes! I am Interested

Bosutinib 400 Mg 30 Tab , 500mg 30 Tab , 100mg 60 Tab Bosuvi Glenmark

Bosutinib 400 Mg 30 Tab , 500mg 30 Tab , 100mg 60 Tab Bosuvi Glenmark
  • Bosutinib 400 Mg 30 Tab , 500mg 30 Tab , 100mg 60 Tab Bosuvi Glenmark
Ask For Price
Product Price :Get Latest Price

Product Details:

Country of OriginMade in India
Packaging Size500mg 30tab,400mg 30tab,100mg 60tab
BrandBosuvi
CompositionBosutinib
ManufacturerGlenmark
Packaging500mg 30tab,400mg 30tab,100mg 60tab
Treatmentchronic myelogenous leukemia and acute lymphoblastic leukemia. Specifically it is used to treat case
Dosage Form500mg,400mg,100mg
Dose Strength500mg,400mg,100mg
CategoryBlood Cancer
DrugBosutinib
Generic NameBosutinib
Packaging Type500mg 30tab,400mg 30tab,100mg 60tab bottle
FormTablet
Therapeutic Useschronic myelogenous leukemia and acute lymphoblastic leukemia. Specifically it is used to treat case
Interactionsan inhibitor of P-glycoprotein (P-gp) and CYP3A4.Hence P-gp and CYP3A4 inhibitors may increase plasm
Side EffectDiarrhoea (~82%) Arterial occlusive events such as stroke or heart attack (44% in patients with
Pregnancy & breast feedingpregnancy may result in harm to the baby
Strength500mg,400mg,100mg

Bosutinib  is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
Originally synthesized by Wyeth, it is being developed by Pfizer.

MechanismIt is an ATP-competitive Bcr-Abl tyrosine-kinase inhibitor with an additional inhibitory effect on SRc family kinases (including Src, Lyn and Hck).It has also shown activity against the receptors for platelet derived growth factor and vascular endothelial growth factor. Bosutinib inhibited 16 of 18 imatinib-resistant forms of Bcr-Abl expressed in murine myeloid cell lines, but did not inhibit T315I and V299L mutant cells.

Bosutinib is metabolized through CYP3A4.

Medical usesBosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

Adverse effects
Very common (>10% frequency):
Diarrhoea (~82%)
Arterial occlusive events such as stroke or heart attack (44% in patients with chronic myeloid leukemia).
Nausea
Myelosuppression
Vomiting (~37%)
Abdominal pain
Raised ALT
Raised AST
Rash
Arthralgia (joint pain)
Fever
Oedema
Fatigue
Cough
Headache
Reduced appetite
Respiratory tract infection

Common (1-10% frequency):

Drug hypersensitivity
Dehydration
Hyperkalaemia (high blood potassium)
Hypophosphataemia (low blood phosphate)
Dizziness
Dysgeusia (distorted sense of taste)
Pericardial effusion
Pleural effusion
QT interval prolongation
Shortness of breath
Gastritis (stomach swellingHepatotoxicity (liver dysfunction/damageAbnormal LFTs
Elevated blood bilirubin levels
GGT increased
Acne
Itchiness
HivesMyalgia (muscle aches)Back pain
Kidney failure
Chest pain
Pain
Muscle weakness
Increased lipase
Increased blood creatinine
Increased blood amylase level
Elevated blood creatine phosphokinase

Uncommon (0.1-1% frequency):

AgranulocytosisAnaphylactic reactionsTinnitus (ringing in the ears)
Pericarditis
Respiratory failure
Acute pulmonary oedema
Pulmonary hypertension
Acute pancreatitis
Gastrointestinal haemorrhage
Liver injury
Erythema multiforme
Erythroderma
Drug eruption
Acute kidney failure
Renal impairment

Contraindications

Bosutinib has two known absolute contraindications, which are: known hypersensitivity to bosutinib and liver impairment.

= InteractionsBosutinib is both a substrate and an inhibitor of P-glycoprotein (P-gp) and CYP3A4.Hence P-gp and CYP3A4 inhibitors may increase plasma levels of bosutinib. Likewise CYP3A4 inducers may reduce plasma concentrations of bosutinib.It may also alter the metabolism and uptake (into the GIT by means of its P-gp inhibitory effects) of other drugs that are substrates for P-gp and CYP3A4.

Carcinogenicity and mutagenicity
Animal studies using up to three-times the clinical exposure (in terms of AUC) to bosutinib have failed to demonstrate any carcinogenic effects. Mutagenic and clastogenic effects were not detected in vitro.

Notes

Including thrombocytopaenia, anaemia, neutropaenia and leucopaenia.

    Including: pneumonia, bronchitis and influenza
Request
Callback


Additional Information:

  • Packaging Details: 500mg 30tab, 400mg 30tab, 100mg 60tab
Yes! I am Interested

Zelgor Tablets

Zelgor Tablets
  • Zelgor Tablets
Get Best Quote
Approx. Price: Rs 10 / PackGet Latest Price

Product Details:

Dose250mg/500mg/1000mg
UsageHospital, Clinical, Personal
Packaging Size250mg /120 tab
Packaging TypeBottles
Type Of MedicinesAllopathic

Request
Callback
Yes! I am Interested

Lenangio Capsules

Lenangio Capsules
  • Lenangio Capsules
Get Best Quote
Approx. Price: Rs 10 / PackGet Latest Price

Product Details:

Packaging SizeBox
Strength (mg)25 mg
Drug NameLenangio

Request
Callback
Yes! I am Interested

Soranib Sorafenib Tablets

Soranib Sorafenib Tablets
  • Soranib Sorafenib Tablets
Get Best Quote
Approx. Price: Rs 10 / PackGet Latest Price

Product Details:

Minimum Order Quantity1 Pack
BrandSoranib
CompositionSorafenib
ManufacturerCipla
Treatmentprimary kidney cancer (advanced renal cell carcinoma),advanced primary liver cancer (hepatocellular
Packaging TypeVial
Dose200 mg
UsageHospital, Clinical
Packaging Size120 Tablets

Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.

Mechanism of action
Sorafenib is a protein kinase inhibitor with activity against many protein kinases, including VEGFR, PDGFR and RAF kinases. Of the RAF kinases, Sorafenib is more selective for c-Raf than B-RAF. (See BRAF (gene)#Sorafenib for details the drug's interaction with B-Raf.)

Sorafenib treatment induces autophagy, which may suppress tumor growth. Based on its 1,3-disubstituted urea structure, Sorafenib is also a potent soluble epoxide hydrolase inhibitor and this activity likely reduces the severity of its adverse effects.

Medical uses -Sorafenib is indicated as a treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC) and thyroid cancer.

Kidney cancer
Clinical trial results, published January 2007, showed that, compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear cell renal cell carcinoma in whom previous therapy has failed. The median progression-free survival was 5.5 months in the sorafenib group and 2.8 months in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55; P<0.01).

Liver cancer At ASCO 2007, results from the SHARP trial were presented, which showed efficacy of sorafenib in hepatocellular carcinoma. The primary endpoint was median overall survival, which showed a 44% improvement in patients who received sorafenib compared to placebo (hazard ratio 0.69; 95% CI, 0.55 to 0.87; p=0.0001). Both median survival and time to progression showed 3-month improvements; however, there was no significant difference in median time to symptomatic progression (p=0.77). There was no difference in quality of life measures, possibly attributable to toxicity of sorafenib or symptoms related to underlying progression of liver disease. Of note, this trial only included patients with Child-Pugh Class A (i.e. mildest) cirrhosis. Because of this trial Sorafenib obtained FDA approval for the treatment of advanced hepatocellular carcinoma. In a randomized, double-blind, phase II trial combining sorafenib with doxorubicin, the median time to progression was not significantly delayed compared with doxorubicin alone in patients with advanced hepatocellular carcinoma. Median durations of overall survival and progression-free survival were significantly longer in patients receiving sorafenib plus doxorubicin than in those receiving doxorubicin alone. A prospective single-centre phase II study which included the patients with unresectable hepatocellular carcinoma (HCC)concluding that the combination of sorafenib and DEB-TACE in patients with unresectable HCC is well tolerated and safe, with most toxicities related to sorafenib. In Australia only indication for sorafenib. Along with renal cell carcinoma, hepatocellular carcinoma is one of the TGA-labelled indications for sorafenib.

Thyroid cancer sorafenib was approved by the FDA for the treat of locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment. The Phase 3 DECISION trial showed significant improvement in progression-free survival but not in overall survival. However, as is known, the side effects were very frequent, specially hand and foot skin reaction.

Desmoid tumors also known as aggressive fibromatosis, after positive results in the first two trial stages. Dosage is typically half of that applied for malignant cancers (400 mg vs 800 mg). NCI are sponsoring this trial.
Request
Callback


Additional Information:

  • Packaging Details: 200mg tab
Yes! I am Interested

Advacan Tablets

Advacan Tablets
  • Advacan Tablets
Get Best Quote
Approx. Price: Rs 10 / PieceGet Latest Price

Product Details:

Packaging TypeTablets
Dose/Strength0.25 mg
Drug NameEverolimus

Request
Callback
Yes! I am Interested

Zytiga Abiraterone

Zytiga Abiraterone
  • Zytiga Abiraterone
Get Best Quote
Approx. Price: Rs 10 / PieceGet Latest Price

Product Details:

UsageHospital, Personal, Clinical
Dose250 mg
Packaging Size120 Tablets

Request
Callback
Yes! I am Interested

Gliotem Medicine

Gliotem Medicine
  • Gliotem Medicine
Get Best Quote
Approx. Price: Rs 10 / PackGet Latest Price

Product Details:

UsageHospital, Clinical
Dose100 mg
Dosage FormCapsule

Request
Callback
Yes! I am Interested

Caditam Medicine

Caditam Medicine
  • Caditam Medicine
Get Best Quote
Approx. Price: Rs 10 / PieceGet Latest Price

Product Details:

Packaging Size10 x 10 Tablets
UsageHospital, Clinical
Dosage FormTablets

Request
Callback
Yes! I am Interested

Eprex

Eprex
  • Eprex
Get Best Quote
Approx. Price: Rs 10 / PackGet Latest Price

Product Details:

Dose4000 IU
UsageClinical, Hospital
Packaging TypeVial

Request
Callback
Yes! I am Interested
X

Explore More Product



Reach Us
Aptcash Enterprises (Proprietor)
Aptcash Enterprises
Shop No. 7, B Wing, Nirmala Niwas, Aai Mai Merwanji Road
Parel, Mumbai - 400012, Maharashtra, India


Call Us
View Mobile No.


Send E-mailSend SMS